Humana (NYSE:HUM) had its price objective increased by BMO Capital Markets from $328.00 to $355.00 in a research note issued to investors on Monday morning. The firm currently has an outperform rating on the insurance provider’s stock.
HUM has been the topic of several other research reports. ValuEngine upgraded shares of Humana from a hold rating to a buy rating in a research note on Monday, April 2nd. Zacks Investment Research upgraded shares of Humana from a hold rating to a buy rating and set a $316.00 price objective on the stock in a research note on Friday, April 13th. Cantor Fitzgerald reiterated a hold rating and set a $250.00 price objective on shares of Humana in a research note on Monday, April 23rd. Piper Jaffray Companies reiterated a buy rating and set a $313.00 price objective on shares of Humana in a research note on Wednesday, April 4th. Finally, Oppenheimer increased their price objective on shares of Humana from $305.00 to $311.00 and gave the stock an outperform rating in a research note on Thursday, May 3rd. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $286.83.
HUM opened at $298.79 on Monday. The stock has a market cap of $41.28 billion, a P/E ratio of 25.52, a price-to-earnings-growth ratio of 1.56 and a beta of 0.92. Humana has a fifty-two week low of $229.84 and a fifty-two week high of $309.18. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, May 2nd. The insurance provider reported $3.36 earnings per share for the quarter, topping the consensus estimate of $3.21 by $0.15. The firm had revenue of $14.28 billion for the quarter, compared to analyst estimates of $14.22 billion. Humana had a net margin of 3.36% and a return on equity of 16.74%. During the same quarter in the prior year, the business earned $2.75 earnings per share. sell-side analysts predict that Humana will post 13.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 27th. Shareholders of record on Friday, June 29th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.67%. The ex-dividend date is Thursday, June 28th. Humana’s dividend payout ratio (DPR) is 17.08%.
In other Humana news, insider Heidi S. Margulis sold 20,621 shares of the company’s stock in a transaction dated Thursday, May 3rd. The shares were sold at an average price of $285.90, for a total value of $5,895,543.90. Following the completion of the transaction, the insider now owns 9,220 shares in the company, valued at approximately $2,635,998. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jody L. Bilney sold 27,461 shares of the company’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $306.46, for a total transaction of $8,415,698.06. Following the completion of the transaction, the insider now owns 11,467 shares of the company’s stock, valued at approximately $3,514,176.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 124,009 shares of company stock valued at $36,887,143. 0.60% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the company. Synovus Financial Corp bought a new position in shares of Humana in the first quarter valued at approximately $100,000. Certified Advisory Corp bought a new position in shares of Humana in the fourth quarter valued at approximately $109,000. Stratos Wealth Partners LTD. boosted its holdings in shares of Humana by 448.7% in the first quarter. Stratos Wealth Partners LTD. now owns 417 shares of the insurance provider’s stock valued at $112,000 after acquiring an additional 341 shares in the last quarter. Financial Gravity Wealth Inc. bought a new position in shares of Humana in the first quarter valued at approximately $113,000. Finally, Summit Trail Advisors LLC boosted its holdings in shares of Humana by 24,611.8% in the first quarter. Summit Trail Advisors LLC now owns 184,103 shares of the insurance provider’s stock valued at $184,000 after acquiring an additional 183,358 shares in the last quarter. Institutional investors and hedge funds own 93.34% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.